“bluebird-bio” Archives

in
Entry Author Date Location
Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More 06/23/17 National
Bluebird Reports Early Results From Upgraded Gene Therapy 06/23/17 Boston
In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths 06/12/17 New York
ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity 06/06/17 National
To Infinity and Beyond: Julian Adams on Missteps and His New Job 04/03/17 Boston
Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? 03/13/17 National
Top Stories of 2016 for Xconomy Boston: Editor’s Picks 12/26/16 Boston
14 For ’17: Key Clinical Data to Watch For Next Year (Part 1) 12/21/16 National
Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More 12/09/16 National
TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round 12/08/16 Boston
The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update 12/05/16 National
Bio Roundup: CAR-T Ups & Downs, Lilly’s Failure, Myeloma & More 12/02/16 National
In Year of CAR-T Trouble, Can Bluebird, Penn Make Headway in Myeloma? 11/30/16 Boston
Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More 11/04/16 National
New Data Show Power, Limits of Bluebird’s Gene Therapy For Blood Diseases 11/03/16 Boston
Third Rock Gets $616M to Grow New Crop of Biotech Startups 10/31/16 Boston
Fred Hutch Team Wants To Move Clean-Room Gene Therapy To Tabletop 10/20/16 Seattle
Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs 10/17/16 New York
Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More 10/14/16 National
With Upgraded Tech, Bluebird Updates Regulatory Path For Gene Therapy 10/13/16 Boston
Aligned With Roche, SQZ Bio Gets $16M to Push Cell Therapies to Clinic 09/30/16 Boston
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push 09/12/16 Boston
Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More 08/05/16 National
More Gene Therapy Momentum as Startup Avrobio Grabs $25M From Atlas, SV 08/02/16 Boston
Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval 07/20/16 San Francisco
Oncorus Bags $57M, Touts Next-Gen Take on Cancer-Fighting Viruses 07/19/16 Boston
With Celgene Deal, Jounce Lands $261M And a “Trusting Partner” 07/19/16 Boston
After Three Deaths, FDA Halts Juno’s Leading CAR-T Trial 07/07/16 Seattle
Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance 05/17/16 Boston
Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance 05/16/16 Boston
Page 1 of 5 next page »